Brain Kynurenine and BH4 Pathways: Relevance to the Pathophysiology and Treatment of Inflammation-Driven Depressive Symptoms
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The prevalence of depressive disorders is growing worldwide, notably due to stagnation in the development of drugs with greater antidepressant efficacy, the continuous large proportion of patients who do not respond to conventional antidepressants, and the increasing rate of chronic medical conditions associated with an increased vulnerability to depressive comorbidities. Accordingly, better knowledge on the pathophysiology of depression and mechanisms underlying depressive comorbidities in chronic medical conditions appears urgently needed, in order to help in the development of targeted therapeutic strategies. In this review, we present evidence pointing to inflammatory processes as key players in the pathophysiology and treatment of depressive symptoms. In particular, we report preclinical and clinical findings showing that inflammation-driven alterations in specific metabolic pathways, namely kynurenine and tetrahydrobiopterin (BH4) pathways, leads to substantial alterations in the metabolism of serotonin, glutamate and dopamine that are likely to contribute to the development of key depressive symptom dimensions. Accordingly, anti-inflammatory interventions targeting kynurenine and BH4 pathways may be effective as novel treatment or as adjuvants of conventional medications rather directed to monoamines, notably when depressive symptomatology and inflammation are comorbid in treated patients. This notion is discussed in the light of recent findings illustrating the tight interactions between known antidepressant drugs and inflammatory processes, as well as their therapeutic implications. Altogether, this review provides valuable findings for moving toward more adapted and personalized therapeutic strategies to treat inflammation-related depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“THERAPEUTIC IMPLICATIONS One of the major issues when dealing with depressive disorders is the heightened resistance to standard antidepressant therapy (Rush et al., 2006).”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“Conversely, raised urine and plasma total biopterin levels are measured in depressed patients (Duch et al., 1984; Garbutt et al., 1985; Knapp and Irwin, 1989; Hashimoto et al., 1994; AbouSaleh et al., 1995), suggesting impaired BH4 metabolism.”
BackgroundOverweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322 · cited 2×
“, 2014) or the presence of chronic inflammatory conditions/diseases (Luppino et al., 2010; Vogelzangs et al., 2012; Hughes and Kumari, 2017).”
BackgroundCytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Self-citationRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“Abundant literature also reports antidepressant effects of anti-TNF-α drugs, such as etanercept or infliximab, in clinical trials (Kekow et al., 2010; Arisoy et al., 2013; Raison et al., 2013; Fleming et al., 2015) and murine models of inflammatory diseases (Haji et al.”
BackgroundO'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278
Self-citationParoxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 3×
“These last symptoms can be prevented by antidepressant treatment, in contrast to neurovegetative symptoms that are not, or only minimally, responsive to this intervention (Musselman et al., 2001; Capuron and Miller, 2011).”
BackgroundLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Mood disorders in the medically ill: scientific review and recommendations
Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.001 · Cited by 1,071
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972
Penninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797 · cited 3×
“To move from correlation to causality, chronic cytokine administration has been shown to induce depression in up to 50% of medically ill patients undergoing cytokine immunotherapy (Musselman et al., 2001; Capuron et al., 2002; Kawase et al., 2016).”
BackgroundSelf-citationMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Agudelo, L. Z., Femenía, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J. C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.051 · Cited by 739
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 1×
“, selective serotonin reuptake blockers: SSRIs, tricyclic antidepressants (TCA) acting on norepinephrine reuptake, and antidepressants acting on both serotonin and norepinephrine reuptake: SNRI] may also act on inflammation since they display anti-inflammatory properties both peripherally and within the brain (Lanquil…”
BackgroundInflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659 · cited 3×
“Compelling evidence supports the notion that antiinflammatory interventions may be effective as novel antidepressants or adjuvants of conventional antidepressants, as long as inflammation and depressive symptoms are comorbid in treated patients (Strawbridge et al., 2015; Kappelmann et al., 2018; Köhler et al., 2016; S…”
BackgroundKynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“More importantly, KP activation correlates with both stretch of brain damages and severity of neuropsychiatric symptoms (Capuron et al., 2002; Raison et al., 2010; Savitz et al., 2015a,b).”
BackgroundInflammation-Induced Anhedonia: Endotoxin Reduces Ventral Striatum Responses to Reward
Eisenberger, N. I., Berkman, E. T., Inagaki, T. K., Rameson, L. T., Mashal, N. M., & Irwin, M. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.010 · Cited by 596 · cited 2×
“…subjects also accentuates weight loss induced by low-calorie diet (Kunesová et al., 2006), weight loss in the context of obesity being associated – as mentioned earlier – with reduced inflammation (Lasselin et al., 2014) and improved depressive symptoms (Emery et al., 2007; Capuron et al., 2011).”
BackgroundInflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584 · cited 3×
“An alternative explanation for the involvement of KP activation in inflammation-related mood symptoms is the generation of neurotoxic glutamatergic kynurenine metabolites, as they have been clinically related to the severity of mood alterations (Capuron et al., 2011; Bay-Richter et al., 2015; Haroon et al., 2017; Schw…”
BackgroundSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
Henry, C. J., Huang, Y., Wynne, A. M., & Godbout, J. P. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.09.002 · Cited by 565
Zhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549
Frenois, F., Moreau, M., O’Connor, J., Lawson, M., Micon, C., Lestage, J., Kelley, K. W., Dantzer, R., & Castanon, N. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.03.005 · Cited by 438 · cited 7×
“…been circumvented by using several reliable and complementary behavioral tests modeling different core symptoms of depression, and by testing mice in these tests only once they have totally recovered from sickness behavior (Frenois et al., 2007; Godbout et al., 2008; O’Connor et al., 2009c).”
BackgroundMethodResultInfluentialSelf-citationWalker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432 · cited 2×
“…receptors, which was already shown to protect against chronic stress-induced depressive-like behavior (Li et al., 2011), are similarly effective regarding LPS-induced behavioral alterations Frontiers in Neuroscience | www.frontiersin.org 9 July 2018 | Volume 12 | Article 499 (Walker et al., 2013).”
BackgroundSharma, S., & Fulton, S. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.48 · Cited by 424 · cited 1×
“…obese (Brandacher et al., 2006; Oxenkrug et al., 2011; Mangge et al., 2014) also suggest the potential involvement of BH4 pathway in obesity-related depressive comorbidity, consistent with impairment of dopamine neurotransmission reported in obesity (Sharma and Fulton, 2013; Krishna et al., 2015).”
BackgroundLayé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
Cancello, R., & Clément, K. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01004.x · Cited by 418 · cited 1×
“Interestingly, weight loss that reduces inflammation and KP activation (Cancello and Clement, 2006; Alemán et al., 2017) correlates with significant mood improvement (mery et al., 2007; Capuron et al., 2011).”
BackgroundLovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · cited 3×
“Accordingly, increased plasma and/or cerebrospinal fluid QA levels have been reported in a plethora of conditions that encompass inflammatory and neurodegenerative damages, together with an increased prevalence of mood symptoms (Capuron et al., 2011; Bay-Richter et al., 2015; Lovelace et al., 2017; O’Farrell and Harki…”
BackgroundCapuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
Self-citationCapuron, L., Schroecksnadel, S., Féart, C., Aubert, A., Higueret, D., Barberger-Gateau, P., Layé, S., & Fuchs, D. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.006 · Cited by 368
Self-citationBroad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder
Hoge, E. A., Brandstetter, K., Moshier, S., Pollack, M. H., Wong, K. K., & Simon, N. M. (2009) · Depression and Anxiety · doi:10.1002/da.20564 · Cited by 343
Vogelzangs, N., Duivis, H. E., Beekman, A. T. F., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J. H., de Jonge, P., & Penninx, B. W. J. H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.8 · Cited by 323
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
Godbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., Castanon, N., Kelley, K. W., Dantzer, R., & Johnson, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301649 · Cited by 299
Self-citationLeighton, S. P., Nerurkar, L., Krishnadas, R., Johnman, C., Graham, G. J., & Cavanagh, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.205 · Cited by 291 · cited 1×
“The first studies strongly supporting this notion report higher circulating levels of inflammatory mediators, including C-reactive protein (CRP), cytokines (particularly interleukin-6, IL-6) and different chemokines, in depressed individuals compared to healthy controls (Dowlati et al., 2010; Leighton et al., 2018).”
BackgroundThe interface of depression and obesity
Jantaratnotai, N., Mosikanon, K., Lee, Y., & McIntyre, R. S. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.07.003 · Cited by 282
Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Neurauter, G., Schrocksnadel, K., Scholl-Burgi, S., Sperner-Unterweger, B., Schubert, C., Ledochowski, M., & Fuchs, D. (2008) · Current Drug Metabolism · doi:10.2174/138920008785821738 · Cited by 274
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272
André, C., Dinel, A.-L., Ferreira, G., Layé, S., & Castanon, N. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.03.012 · Cited by 241
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301362 · Cited by 229 · cited 1×
“Clinical studies also reveal some functional alterations of the dopaminergic reward system, in association with impairment in motivation and motor slowing (Capuron et al., 2007; Eisenberger et al., 2010; Capuron et al., 2012).”
BackgroundSelf-citationProtracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge
Wynne, A. M., Henry, C. J., Huang, Y., Cleland, A., & Godbout, J. P. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.05.011 · Cited by 224
Réus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
Depressive symptoms and metabolic syndrome: is inflammation the underlying link?
Capuron, L., Su, S., Miller, A. H., Bremner, J. D., Goldberg, J., Vogt, G. J., Maisano, C., Jones, L., Murrah, N. V., & Vaccarino, V. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.019 · Cited by 219
Self-citationFelger, J. C., Mun, J., Kimmel, H. L., Nye, J. A., Drake, D. F., Hernandez, C. R., Freeman, A. A., Rye, D. B., Goodman, M. M., Howell, L. L., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.115 · Cited by 214
Overweight and Obesity Affect Treatment Response in Major Depression
Kloiber, S., Ising, M., Reppermund, S., Horstmann, S., Dose, T., Majer, M., Zihl, J., Pfister, H., Unschuld, P. G., Holsboer, F., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.001 · Cited by 208 · cited 2×
“Moreover, in line with recent data suggesting that elevated basal inflammation, as reported in obesity and metabolic syndrome, may contribute to impair the therapeutic efficiency of conventional antidepressant treatment (Kloiber et al., 2007; Toups et al., 2013), a corollary question arises as to whether inflammatory…”
BackgroundResultSchedlowski, M., Engler, H., & Grigoleit, J.-S. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.09.015 · Cited by 195
Role of Adiposity-Driven Inflammation in Depressive Morbidity
Capuron, L., Lasselin, J., & Castanon, N. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.123 · Cited by 182
Self-citationFelger, J. C., Li, L., Marvar, P. J., Woolwine, B. J., Harrison, D. G., Raison, C. L., & Miller, A. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.010 · Cited by 176
Parrott, J. M., Redus, L., Santana-Coelho, D., Morales, J., Gao, X., & O'Connor, J. C. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.200 · Cited by 174
Lestage, J., Verrier, D., Palin, K., & Dantzer, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00014-4 · Cited by 170 · cited 1×
“These findings prompted a surge of interest for the involvement of KP enzymes and metabolites in inducing these symptoms, starting by the enzyme indoleamine 2,3-dioxygenase (IDO) that catalyzes the first and rate-limiting step of tryptophan metabolism along the KP (Lestage et al., 2002; Moreau et al., 2005; André et a…”
BackgroundUrano (2001) · doi:10.1074/jbc.m102237200 · Cited by 139
Regulation of Tetrahydrobiopterin Synthesis and Bioavailability in Endothelial Cells
Shi, W., Meininger, C. J., Haynes, T. E., Hatakeyama, K., & Wu, G. (2004) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:41:3:415 · Cited by 137
Merali, Z., Brennan, K., Brau, P., & Anisman, H. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1273-1 · Cited by 127 · cited 2×
“Consistent with clinical findings, both acute or chronic immune challenges in rodents induce sustained depressive-like and anxiety-like behaviors (Merali et al., 2003; Frenois et al., 2007; Moreau et al., 2008; Klaus et al., 2016).”
BackgroundParrott, J. M., Redus, L., & O’Connor, J. C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0590-y · Cited by 112
Lasselin, J., Magne, E., Beau, C., Ledaguenel, P., Dexpert, S., Aubert, A., Layé, S., & Capuron, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2673 · Cited by 96 · cited 1×
“, 2006), weight loss in the context of obesity being associated – as mentioned earlier – with reduced inflammation (Lasselin et al., 2014) and improved depressive symptoms (Emery et al.”
BackgroundSelf-citationWoo, Y., Seo, H.-J., McIntyre, R., & Bahk, W.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010080 · Cited by 79
Targeting cytokines in reduction of depressive symptoms: A comprehensive review
Shariq, A. S., Brietzke, E., Rosenblat, J. D., Barendra, V., Pan, Z., & McIntyre, R. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.003 · Cited by 72
Anti-depressant medication use and C-reactive protein: Results from two population-based studies
Hamer, M., Batty, G., Marmot, M. G., Singh-Manoux, A., & Kivimäki, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.09.013 · Cited by 71 · cited 1×
“Of note, the immunemodulatory impact of antidepressants differs depending on their class, with SSRI and SNRI drugs being mostly anti-inflammatory, while TCAs rather displaying in some studies pro-inflammatory properties (Hamer et al., 2011; Vogelzangs et al., 2012; Nazimek et al., 2016; Chen et al., 2018).”
BackgroundToups, M. S. P., Myers, A. K., Wisniewski, S. R., Kurian, B., Morris, D. W., Rush, A. J., Fava, M., & Trivedi, M. H. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000000 · Cited by 59
Cited by
Dietary fiber and its associations with depression and inflammation
Swann, O. G., Kilpatrick, M., Breslin, M., & Oddy, W. H. (2020) · Nutrition Reviews · doi:10.1093/nutrit/nuz072 · Cited by 185
Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry
Fanet, H., Capuron, L., Castanon, N., Calon, F., & Vancassel, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200729103529 · Cited by 134
Self-citationSen, Z. D., Danyeli, L. V., Woelfer, M., Lamers, F., Wagner, G., Sobanski, T., & Walter, M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.020 · Cited by 65
Teixeira, A. L., Martins, L. B., Berk, M., & Bauer, M. E. (2022) · Clinical Science · doi:10.1042/cs20211106 · Cited by 22
Metadata
- Authors
- Vancassel, S., Capuron, L., & Castanon, N.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-07-24
- Volume
- 12
- Pages
- 499-499
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2883826253
- Cited by
- 94
- References
- 64
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.